citing AstraZeneca's ongoing capital expenditures including its $300 million investment announced on Tuesday in a facility in Maryland for discovery and development of cell therapies. "There is a ...

By leveraging our cutting-edge discovery capabilities and AstraZeneca's expertise in drug ... The company is building its robust portfolio and differentiated pipeline through internal R&D ...

AstraZeneca is building a cell therapy portfolio that ... Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation ...

AstraZeneca has signed a deal worth ... “We are applying AI throughout our discovery and development process, through building in-house capabilities and through collaborations such as with ...

The consortium's goal is to build the largest enterprise AI supercomputer in Sweden, once it becomes operational.

“AstraZeneca is focused on building the transformative oncology ... considered ‘undruggable’ using conventional drug discovery approaches, and collaborations with biotechs Accent ...

The first thing Promise Bio CEO Ronel Veksler wants you to know about the biotech company he co-founded is that it’s not another AI drug discovery company. Instead, he’s looking to bring ...

is possible given AstraZeneca's position as one of the leading pharmaceutical companies on artificial intelligence integration in drug discovery and data science. Currently, AZN shares are trading ...

This is the latest in a string of tie-ups by Anglo-Swedish drugmaker AstraZeneca to use artificial intelligence for drug discovery and development, including a $247 million deal with U.S.-based ...